Interpatium

Interpatium is a biotechnology company focused on developing novel therapeutics for neurodegenerative and neuroinflammatory diseases by targeting the neurovascular unit. The company's lead program is a first-in-class monoclonal antibody designed to neutralize the toxic, pro-inflammatory effects of fibrin, a blood protein that leaks into the brain through a damaged blood-brain barrier. Unlike traditional anticoagulants, Interpatium's approach targets the inflammatory domain of fibrin without interfering with its essential blood-clotting functions. This strategy aims to halt neurodegeneration and promote repair in conditions such as Alzheimer's disease and Multiple Sclerosis. The company was founded based on pioneering research from the Gladstone Institutes and the University of California, San Francisco. Interpatium is backed by a syndicate of leading life science investors, including MRL Ventures Fund and Casdin Capital.